Evidence map›Paper›PMID 27536369›Full record

ArticleUnited European gastroenterology journal2016

Interval cancers in a national colorectal cancer screening programme.

Robert Jc Steele, Greig Stanners, Jaroslaw Lang, David H Brewster, Francis A Carey, Callum G Fraser

Abstract read
In one paragraph

Article in United European gastroenterology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Robert Jc SteeleCentre for Research into Cancer Prevention and Screening (CRiPS), University of Dundee, Dundee, UK.
Greig StannersInformation Services, National Services Scotland, Edinburgh, UK.
Jaroslaw LangInformation Services, National Services Scotland, Edinburgh, UK.
David H BrewsterScottish Cancer Registry, Edinburgh, UK.
Francis A CareyDepartment of Pathology, Ninewells Hospital and Medical School, Dundee, UK.
Callum G FraserCentre for Research into Cancer Prevention and Screening (CRiPS), University of Dundee, Dundee, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLittle is known about interval cancers (ICs) in colorectal cancer (CRC) screening.

objectiveThe purpose of this study was to identify IC characteristics and compare these with screen-detected cancers (SCs) and cancers in non-participants (NPCs) over the same time period.

designThis was an observational study done in the first round of the Scottish Bowel Screening Programme. All individuals (772,790), aged 50-74 years, invited to participate between 1 January 2007 and 31 May 2009 were studied by linking their screening records with confirmed CRC records in the Scottish Cancer Registry (SCR). Characteristics of SC, IC and NPC were determined.

resultsThere were 555 SCs, 502 ICs and 922 NPCs. SCs were at an earlier stage than ICs and NPCs (33.9% Dukes' A as against 18.7% in IC and 11.3% in NPC), screening preferentially detected cancers in males (64.7% as against 52.8% in IC and 59.7% in NPC): this was independent of a different cancer site distribution in males and females. SC in the colon were less advanced than IC, but not in the rectum.

conclusionICs account for 47.5% of the CRCs in the screened population, indicating approximately 50% screening test sensitivity: guaiac faecal occult blood testing (gFOBT) sensitivity is less for women than for men and gFOBT screening may not be effective for rectal cancer.

Indexed as

Colorectal cancer screeningfaecal occult blood testinterval cancernon-participant cancerscreen-detected cancer

Identifiers

PMID27536369
PMCPMC4971793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.